Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Closed 08-05 16:00:00 EDT

514.12

+6.56

+1.29%

盘后514.12

+0.000.00%

19:34 EDT

High517.00	Low503.65	Vol349.53K
Open510.88	D1 Closing507.56	Amplitude2.63%
Mkt Cap11.85B	Tradable Cap7.12B	Total Shares23.06M
T/O178.87M	T/O Rate2.52%	Tradable Shares13.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":514.12,"timestamp":1785960000000,"preClose":507.56,"halted":0,"volume":349534,"hourTrading":{"tag":"盘后","latestPrice":514.12,"preClose":514.12,"latestTime":"19:34 EDT","volume":27055,"amount":13909580.7648,"timestamp":1785972842036,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01292458034518087,"floatShares":13850000,"shares":23055522,"eps":-13.421304,"marketStatus":"Closed","change":6.56,"latestTime":"08-05 16:00:00 EDT","open":510.88,"high":517,"low":503.645,"amount":178872102.063,"amplitude":0.026312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.421304,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786003200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":507.56,"preHourTrading":{"tag":"盘前","latestPrice":509.24,"preClose":507.56,"latestTime":"09:27 EDT","volume":120,"amount":60751.2,"timestamp":1785936460001,"change":1.68,"changeRate":0.00331,"amplitude":0.047369},"postHourTrading":{"tag":"盘后","latestPrice":514.12,"preClose":514.12,"latestTime":"19:34 EDT","volume":27055,"amount":13909580.7648,"timestamp":1785972842036,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.492837,"impliedVol":0.4202,"impliedVolPercentile":0.0876},"requestUrl":"/m/hq/s/MDGL/wiki","defaultTab":"wiki","newsList":[{"id":"2657569703","title":"Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569703","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569703?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:10","pubTimestamp":1785874254,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals Q3 revenue jumps on REDEMPLO growthOverviewRNAi therapeutics developer's fiscal Q3 revenue rose sharply, beating analyst expectationsCompany posted a wider net loss as operat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4139","MEDI","ARWR","RYTM","INDV","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656531521","title":"Madrigal upgraded to Outperform from Peer Perform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2656531521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656531521?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:25","pubTimestamp":1785835527,"startTime":"0","endTime":"0","summary":"Wolfe Research upgraded Madrigal Pharmaceuticals (MDGL) to Outperform from Peer Perform with a $605 price target The firm says the shares overcorre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656798983","title":"Madrigal Pharmaceuticals is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2656798983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656798983?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:14","pubTimestamp":1785759240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656032031","title":"Madrigal Pharmaceuticals price target lowered to $962 from $964 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2656032031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656032031?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:45","pubTimestamp":1785750349,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $962 from $964 and keeps an Overweight rating o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-962-from-964-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/madrigal-pharmaceuticals-price-target-lowered-to-962-from-964-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190573768","title":"Movement Alert｜Madrigal Pharmaceuticals Falls 5.07% in Regular Trading, Q2 Earnings Loss Widening Extends Selling Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1190573768","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190573768?lang=en_us&edition=fundamental","pubTime":"2026-07-31 22:09","pubTimestamp":1785506988,"startTime":"0","endTime":"0","summary":"On July 31, Madrigal Pharmaceuticals declined 5.07% in regular trading, trading at $468.38 per share with turnover of $84.64 million, extending the prior session's sharp selloff.The continued decline...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655335701","title":"Madrigal Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $543 from $553","url":"https://stock-news.laohu8.com/highlight/detail?id=2655335701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655335701?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:32","pubTimestamp":1785493969,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X1S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820385","title":"Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820385","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655820385?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:12","pubTimestamp":1785442328,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences Q2 adjusted EPS beats expectations, revenue rises on product portfolio growthOverviewU.S. biopharma firm's Q2 revenue rose 39% yr/yr, driven by product portfolio growthAdjusted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W1HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4548","BK4139","LU2324357040.USD","LU2065171311.SGD","LU0320765992.SGD","LU0154245673.USD","LU0882574055.USD","LU0889565916.HKD","BK4588","LU2065170008.USD","BK4585","LU0114720955.EUR","GNMX","MDGL","LU0154245756.USD","LU0823416689.USD","NBIX","ALNY","PBE","LU2065169927.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655802975","title":"Madrigal Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655802975","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655802975?lang=en_us&edition=fundamental","pubTime":"2026-07-31 01:10","pubTimestamp":1785431414,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryMadrigal Pharmaceuticals IncMDGL.OQreported a quarterly adjusted loss of $1.13 per share for the quarter en","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL8N43W3DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157366999","title":"Movement Alert｜Madrigal Pharmaceuticals Falls 12.78% in Regular Trading, Q2 Revenue Beats Expectations but Year-over-Year Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=1157366999","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157366999?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:09","pubTimestamp":1785424160,"startTime":"0","endTime":"0","summary":"On July 30, Madrigal Pharmaceuticals declined 12.78% in regular trading, trading at $476.98/share, with turnover of $347 million. The sell-off was triggered by the company's Q2 earnings report...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154380323","title":"Stock Track | Madrigal Pharmaceuticals Plummets 7.56% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1154380323","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154380323?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:35","pubTimestamp":1785418503,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) shares tumbled 7.56% in pre-market trading on Thursday after the company reported second-quarter financial results that showed a widening net loss and escalating...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173806056","title":"Movement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1173806056","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173806056?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:19","pubTimestamp":1785413989,"startTime":"0","endTime":"0","summary":"On July 30, Madrigal Pharmaceuticals fell 6.74% in pre-market trading, trading at $508.12/share, with turnover of $754,800.The decline came despite the company reporting second-quarter results that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655724788","title":"Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra","url":"https://stock-news.laohu8.com/highlight/detail?id=2655724788","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655724788?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:12","pubTimestamp":1785413548,"startTime":"0","endTime":"0","summary":"Alnylam Q2 revenue rises 67% on increased demand for AMVUTTRAOverviewRNAi therapeutics maker's Q2 revenue rose 67% yr/yr but missed analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCom","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0QN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4588","LU0882574055.USD","BIIB","BK4533","LU0234570918.USD","LU0889565916.HKD","GNMX","IE00B894F039.SGD","MDGL","BK4532","PBE","BK4548","IONS","LU0109394709.USD","LU0320765992.SGD","ALNY","IE00B19Z9P08.USD","BK4585","BK4139","BMED","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105813826","title":"Stock Track | Madrigal Pharmaceuticals Plunges 6.14% in Pre-market as Q2 Loss Widens and Expenses Surge Despite Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1105813826","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105813826?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:42","pubTimestamp":1785411761,"startTime":"0","endTime":"0","summary":"Shares of Madrigal Pharmaceuticals (MDGL) tumbled 6.14% in pre-market trading on Thursday, as the company's second-quarter 2026 financial results showed a widening net loss and escalating operating...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655089879","title":"Madrigal Q2 FY26 Net Loss Widens to $57.9 Million; Net Sales Rise 71% to $364.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655089879","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655089879?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:21","pubTimestamp":1785410476,"startTime":"0","endTime":"0","summary":"Madrigal Q2 FY26 net loss widens to $57.9 million; net sales rise 71% to $364.3 millionMadrigal posted 2Q 2026 net sales of $364.3 million, up 71% year over year.Net loss widened to $57.9 million; los","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL4S07yp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655266879","title":"Madrigal Pharmaceuticals Q2 Product Revenue USD 364.252 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655266879","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655266879?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:17","pubTimestamp":1785410276,"startTime":"0","endTime":"0","summary":"Jul 30 (Reuters) - Madrigal Pharmaceuticals Q2 net income USD -57.939 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 30-JUL-202610:12:46.453 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nRSD9qzp4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655879459","title":"Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2655879459","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655879459?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:15","pubTimestamp":1785410129,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demandOverviewU.S. MASH drugmaker's Q2 revenue rose 71% yr/yr on strong Rezdiffra demandCompany's Q2 net loss widened as operating expenses i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","LU0109394709.USD","LU0320765992.SGD","BK4532","PBE","BK4139","LU0889565916.HKD","MDGL","BK4588","THNR","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","VKTX","IE00B894F039.SGD","BK4533","BK4585","BK4599","BIIB","OZEM","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655791218","title":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q2 Net Loss $1.99 a Share, vs. FactSet Est of $2.68 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2655791218","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655791218?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:13","pubTimestamp":1785410003,"startTime":"0","endTime":"0","summary":"Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q2 Net Loss $1.99 a Share, vs. FactSet Est of $2.68 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655762058","title":"Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655762058","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655762058?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:03","pubTimestamp":1785409401,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60792726/madrigal-pharmaceuticals-q2-eps-1-99-beats-2-50-estimate-sales-364-252m-beat-353-178m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655779876","title":"Madrigal Pharmaceuticals Q2 EPS USD -1.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2655779876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655779876?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:00","pubTimestamp":1785409204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLX5LJVZ3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4139","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655087659","title":"Madrigal Pharmaceuticals Q2 Operating Income USD -56.308 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655087659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655087659?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:00","pubTimestamp":1785409204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLX5LJVZ3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","MDGL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":-0.058},{"period":"1month","weight":-0.0389},{"period":"3month","weight":-0.0596},{"period":"6month","weight":0.0952},{"period":"1year","weight":0.6262},{"period":"ytd","weight":-0.1284}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.113604},{"month":6,"riseRate":0.7,"avgChangeRate":0.037265},{"month":7,"riseRate":0.1,"avgChangeRate":-0.084013},{"month":8,"riseRate":0.636364,"avgChangeRate":0.096089},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}